Bromide

Bromide

SCHEMBL1415219

C=CC[n+]1cccc2ccccc21.[Br-]

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 17/20 0.72
BCHE P06276 16/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL6704516 0.98 ACHE (0.70) ACHEBCHE
SCHEMBL250421 0.98 ACHE (0.69) ACHEBCHE
Bromide SCHEMBL6704511 0.96 ACHE (0.68) ACHEBCHE
Iodide SCHEMBL3434358 0.96 ACHE (0.67) ACHEBCHE
Hydrochloric Acid SCHEMBL2578272 0.96 ACHE (0.72) ACHEBCHE
Ammonia Solution, Strong SCHEMBL6704056 0.94 ACHE (0.70) ACHEBCHE
Hydrochloric Acid SCHEMBL6704052 0.93 ACHE (0.68) ACHEBCHE
SCHEMBL4234816 0.85 ACHE (0.54) ACHEBCHE
Bromide SCHEMBL20138572 0.84 ACHE (1.00) ACHEBCHE
Bromide SCHEMBL18154065 0.84 ACHE (1.00) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007002070-A2 ZINC-NICKEL ALLOY ELECTROPLATING SYSTEM PAVCO, INC. (US) 2007-01-04 WO claimed
US-20060283715-A1 ZINC-NICKEL ALLOY ELECTROPLATING SYSTEM PAVCO, INC. 2006-12-21 US claimed
CN-107427869-B Heavy metal fixing agent for treating ash and method for treating ash using same 栗田工业株式会社 2021-02-02 CN disclosed
US-20110144079-A1 ANTIMICROBIAL SYSTEM THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2011-06-16 US disclosed
EP-2293669-A2 ANTIMICROBIAL SYSTEM The Queen's University of Belfast (GB) 2011-03-16 EP disclosed
WO-2009125222-A2 ANTIMICROBIAL SYSTEM THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-10-15 WO disclosed
WO-2007002070-A2 ZINC-NICKEL ALLOY ELECTROPLATING SYSTEM PAVCO, INC. (US) 2007-01-04 WO disclosed
US-20060283715-A1 ZINC-NICKEL ALLOY ELECTROPLATING SYSTEM PAVCO, INC. 2006-12-21 US disclosed
JP-2003012487-A BEAUTY LIQUID FOR LASER TREATMENT AND METHOD FOR LASER TREATMENT YA MAN LTD 2003-01-15 JP disclosed
US-4014759-A ASCORBIC, ISOASCORBIC OR ERYTHORBIC ACID, REACTION PRODUCT OF AROMATIC SULFINATE AND ALDEHYDE M & T CHEMICALS INC. (US) 1977-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144079-A1 ANTIMICROBIAL SYSTEM PIK3C3, POLR1C, LTN1 ACHE 4110/4885BCHE 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.